Trial Profile
A study evaluating infections in patients receiving Ibrutinib for treatment of lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017